Intra-articular Infiltration of Platelet-Rich Fibrin vs Corticosteroid in Mild to Moderate Knee Osteoarthritis
A legfontosabb adatok
- Ki végzi
- Federal University of São Paulo
- Hol
- Brazília1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 4. fázis
- Résztvevők
- 90 fő, tervezett
- Kezdés
- 2025. jún. 1.
- Várható befejezés
- 2027. szept. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Platelet-rich fibrin (PRF)
- Corticosteroid
- A regiszteradat frissítve
- 2025. április 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults aged 50 or older with mild or moderate knee osteoarthritis (wear of the knee joint). Their knee pain has not improved with non-surgical treatment.
- Életkor
- 50 years or older
- Nem
- All sexes
- A betegség stádiuma
- Mild or moderate knee osteoarthritis, grade 2 or 3 on X-ray by the Kellgren-Lawrence scale. Average pain score above 40/100 for at least 7 days in the previous month.
- Korábbi kezelés
- No improvement after non-surgical treatment for at least 3 months. No NSAIDs (anti-inflammatory painkillers) in the last month. No corticosteroids in the last 3 months. No knee injection of corticosteroid or HA in the last 6 months.
- Biomarker vagy leletérték
- Platelets must not be below 150,000. People with diabetes need HbA1c of 7 or less.
A részvétel fő kizáró okai
- Knee bent inward or outward by more than 10º (over 4º varus or 16º valgus)
- BMI above 35 or below 18, or smoking
- Autoimmune rheumatic disease, chronic kidney disease, bleeding disorders, severe heart disease, infections or weak immune system
- Active or treated cancer, psychiatric disorders, pregnancy or possible pregnancy
- Off work on disability or worker's compensation benefits
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Age 50 years or older
- Who have not improved with non-surgical treatment for at least 3 months, ability to sign a consent form, average visual analog scale > 40/100 (over at least 7 days in the previous month)
- Mild or moderate knee osteoarthritis diagnosed by radiographic imaging grade 2 or 3 according to the Kellgren-Lawrence classification
Ki nem vehet részt
- use of corticosteroids in the last 3 months
- recent intra-articular corticosteroid injection or recent HA injection (in the last 6 months)
- -Absence from work due to disability benefits or income reduction assistance (worker's compensation). Whenever one of the investigators believes that a participant may be simulating a worse health condition than reality to receive financial assistance with work absence, they will be excluded from the study
- Autoimmune inflammatory disease - rheumatological
- Chronic kidney disease
- severe cardiovascular diseases
- infections or immunodeficiencies
- active or treated malignant neoplasia
- psychiatric disorders
- Diabetes - with HbA1c > 7
- platelets < 150,000
- The following non-inclusion criteria will be observed:
- Angular deviation >10º of varus or valgus in relation to the anatomical neutral axis in the coronal plane assessed clinically with a goniometer (anatomical axis of the femur x anatomical axis of the tibia > 4º varus or > 16º valgus)
- Body Mass Index (BMI)>35 or <18
- Smoking
- Coagulopathies
- use of NSAIDs in the last month
- pregnancy or suspected pregnancy
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Methodology: Randomized double-blind clinical trial comparing intra-articular injection of Platelet-Rich Fibrin (PRF) versus intra-articular injection of corticosteroids in mild to moderate arthrosis of the knee. Inclusion criteria: Age 50 years or older, who have not improved with non-surgical treatment for at least 3 months, ability to sign informed consent, mean visual analogue scale > 40/100 (over at least 7 days during the month anterior), mild or moderate knee arthrosis diagnosed by grade 2 or 3 radiographic imaging according to the Kellgren-Lawrence classification. Inclusion criteria: angular deviation >10º of varus or valgus in relation to the anatomical neutral axis in the coronal plane clinically evaluated with a goniometer (femur anatomical axis x tibial anatomical axis > 4th varus or > 16th valgus), BMI >35 or <18, smoking , autoimmune inflammatory disease - rheumatologic, diabetes - with glycated Hb > 7, chronic kidney disease, coagulopathies, severe cardiovascular diseases, infections or immunodeficiencies, malignant neoplasm in activity or under treatment, use of NSAIDs in the last month, use of corticosteroids in the last 3 months, platelets < 150,000, recent intra-articular corticosteroid infiltration or recent Hyaluronic acid infiltration (within the last 6 months), pregnancy or suspected pregnancy, psychiatric disorders. Exclusion criteria: when one of the investigators considers that the participant may be simulating a worse health state than the real one in order to receive financial assistance with the absence from work, he will be excluded from the work. Primary outcome: WOMAC. Secondary outcomes: Visual Analogue Pain Scale. Evaluation moments: inclusion and after the procedure at 3, 6, 12, 18 and 24 months. Sample calculation: 90 patients, 45 patients in each group, considering 15% loss to follow-up and aiming to reach a power of 0.8 and an alpha value of 0.5.
A vizsgálat 2 csoportja
- CorticoidMár használt kezelés, összehasonlításként
The procedures will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. In this group, 40ml of peripheral blood will also be collected and placed for centrifugation. During the preparation for the application, a nurse (who will not participate in the study) will have a list of the randomization and will prepare the material in an opaque syringe (blinding both the applicator and the patient). In this group of patients, a solution of 10ml containing 40mg of Triamcinolone will be administered in the first application and 10ml of saline in the second and third applications, with intervals of 14 to 28 days between the applications. The applications will be performed on an outpatient basis, with patients being advised to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated.
Kezelés: Corticosteroid
- platelet-rich fibrinA vizsgált kezelés
The Intervention Group consists of the intra-articular application of PRF in the knee. The applications will be performed by the same doctor. The patients will be blinded so that they do not know to which group each individual belongs. A total of 3 applications of PRF will be conducted, with intervals of 14 to 28 days between them. 10ml of PRF will be applied intra-articularly, on an outpatient basis, with patients being instructed to follow the same protocol for physiotherapy and rehabilitation. There will be no restrictions on load or range of motion in the knee being treated.
Kezelés: Platelet-rich fibrin (PRF)
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. április 2.